These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 22315615)

  • 1. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.
    Ogata A; Tanaka T
    Int J Rheumatol; 2012; 2012():946048. PubMed ID: 22315615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
    Tanaka T; Kishimoto T
    Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
    Tanaka T
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 and rheumatoid arthritis.
    Yoshida Y; Tanaka T
    Biomed Res Int; 2014; 2014():698313. PubMed ID: 24524085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
    Tanaka T; Narazaki M; Kishimoto T
    FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
    Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F
    Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin (IL-6) Immunotherapy.
    Tanaka T; Narazaki M; Kishimoto T
    Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 28778870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interleukin-6 in autoimmune uveitis.
    Mesquida M; Molins B; Llorenç V; de la Maza MS; Adán A
    Autoimmun Rev; 2017 Oct; 16(10):1079-1089. PubMed ID: 28778705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
    Mihara M; Nishimoto N; Ohsugi Y
    Expert Opin Biol Ther; 2005 May; 5(5):683-90. PubMed ID: 15934843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis.
    Hennigan S; Kavanaugh A
    Ther Clin Risk Manag; 2008 Aug; 4(4):767-75. PubMed ID: 19209259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.
    Hushaw LL; Sawaqed R; Sweis G; Reigle J; Gopal A; Brandt D; Sweis N; Curran J; Niewold TB; Sweiss NJ
    Ther Clin Risk Manag; 2010 Apr; 6():143-52. PubMed ID: 20421913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 in inflammation, immunity, and disease.
    Tanaka T; Narazaki M; Kishimoto T
    Cold Spring Harb Perspect Biol; 2014 Sep; 6(10):a016295. PubMed ID: 25190079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.